Table 1 Clinical characteristics of all and selected patients for this study included in HOVON-84 and PETAL trials
Characteristic | HOVON84-NGS (n = 208) | HOVON84 (n = 574) | p-value | PETAL-NGS (n = 204) | PETAL (n = 609) | p-value | p-value (HOVON84-NGS vs. PETAL-NGS) |
---|---|---|---|---|---|---|---|
Age | 7,97E-01 | 6,26E-02 | 0.005382 | ||||
≤60 | 67 (32%) | 192 (33%) | 94 (46%) | 292 (48%) | |||
>60 | 141 (68%) | 382 (67%) | 110 (54%) | 304 (50%) | |||
Missing | 0 (0%) | 0 (0%) | 0 (0%) | 13 (2%) | |||
Sex | 8,08E-01 | 3,27E-01 | 0.07077 | ||||
Female | 102 (49%) | 275 (48%) | 81 (40%) | 267 (44%) | |||
Stage of disease | 4,99E-02 | 9,19E-01 | 1,47E-10 | ||||
I | 0 (0%) | 0 (0%) | 40 (20%) | 115 (19%) | |||
II | 38 (18%) | 114 (20%) | 41 (20%) | 135 (22%) | |||
III | 48 (23%) | 177 (31%) | 42 (21%) | 131 (21%) | |||
IV | 122 (59%) | 283 (49%) | 81 (40%) | 227 (37%) | |||
Missing | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1%) | |||
Serum LDH level | 6,71E-01 | 7,64E-01 | 0.03018 | ||||
≤ ULN | 74 (36%) | 195 (34%) | 95 (47%) | 273 (44%) | |||
> ULN | 134 (64%) | 379 (66%) | 109 (53%) | 335 (55%) | |||
Missing | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1%) | |||
ECOG ps | 7,21E-01 | 2,23E-01 | 0.3309 | ||||
0 | 112 (54%) | 304 (53%) | 106 (52%) | 269 (44%) | |||
1 | 67 (32%) | 201 (35%) | 77 (38%) | 276 (45%) | |||
2 | 27 (13%) | 66 (11%) | 19 (9%) | 59 (10%) | |||
Missing | 2 (1%) | 3 (1%) | 2 (1%) | 5 (1%) | |||
# Extranodal sites | 1 | 9,48E-01 | 0.07217 | ||||
≤ 1 | 115 (55%) | 318 (55%) | 139 (68%) | 410 (67%) | |||
> 1 | 80 (39%) | 221 (39%) | 65 (32%) | 198 (32%) | |||
missing | 13 (6%) | 35 (6%) | 0 (0%) | 1 (1%) | |||
IPI score | 9,53E-01 | 7,19E-01 | 3,00E-06 | ||||
0 | 0 (0%) | 0 (0%) | 25 (12%) | 73 (12%) | |||
1 | 14 (7%) | 40 (7%) | 52 (25%) | 151 (25%) | |||
2 | 55 (26%) | 149 (26%) | 45 (22%) | 158 (26%) | |||
3 | 70 (34%) | 211 (37%) | 48 (24%) | 127 (22%) | |||
4 | 44 (21%) | 114 (20%) | 28 (14%) | 60 (11%) | |||
5 | 10 (5%) | 22 (4%) | 6 (3%) | 19 (3%) | |||
Missing | 15 (7%) | 38 (6%) | 0 (0%) | 1 (1%) |